© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Author | Mitchell S. Anscher, MD, FACR, FACRO, FASTRO
Articles
Favorable vs Unfavorable Intermediate-Risk Prostate Cancer: A Review of the New Classification System and Its Impact on Treatment Recommendations
March 15, 2016
The population of patients with intermediate-risk prostate cancer are a large and heterogeneous group with highly variable prognoses, which present a challenge to efforts to develop standardized treatment recommendations.